Fractyl Health, Inc. GUTS 深 沪
等待开盘 09-30 09:30:00 美东时间
1.50
+0.160
+11.94%
华盛通- 最 高1.54
- 今 开1.40
- 成交量 1315.06万股
- 最 低 1.22
- 昨 收 1.34
- 总市值 7543.35万
- 52周最高 3.481
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.825
- 委 比 96.79%
- 总股本 5028.90万
- 历史最高 14.50
- 量 比 0.83
- 振 幅 23.88%
- 历史最低 0.825
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
Fractyl Health Reveals Promising REMAIN-1 Study Results
The latest update is out from Fractyl Health, Inc. ( ($GUTS) ). On September 26...
09-26 19:28
Fractyl Health Study Shows Revita Helps Prevent Weight Regain After Stopping Popular GLP-1 Drugs
Fractyl Health, Inc.
09-26 19:01
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Fractyl Health announced positive results from the REMAIN-1 Midpoint Cohort study, showing that Revita, an endoscopic duodenal mucosal resurfacing procedure, helped patients lose an additional 2.5% of body weight after stopping GLP-1 drugs, while sham-treated patients regained 10%. The study met its 3-month efficacy endpoint with strong statistical significance (p=0.014) and demonstrated excellent safety and tolerability. These findings suggest R...
09-26 11:00
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
HC Wainwright & Co. Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Fractyl Health (NASDAQ:GUTS) with a Buy rating and announces Price Target of $9.
09-15 19:15
Fractyl Health Appoints New Directors Amid Leadership Changes
Fractyl Health, Inc. ( ($GUTS) ) has provided an update. On August 29, 2025, Fr...
09-03 19:29
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Fractyl Health appoints Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors, strengthening its leadership as it advances Revita and prepares for Rejuva's first-in-human study. Dr. Thompson brings expertise in endoscopic treatments for obesity and metabolic diseases, while Sheffield offers extensive healthcare investment experience. These additions aim to support Fractyl's growth and innovation in metabolic care. Amy Schulman st...
09-03 11:00
Ladenburg Thalmann Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $3.6
Ladenburg Thalmann analyst Jeff Cohen initiates coverage on Fractyl Health (NASDAQ:GUTS) with a Buy rating and announces Price Target of $3.6.
08-28 20:41
